8
Nov
2026
The Best AI Health Innovators Have a Feel for People
Abba Eban observed in 1967 that wisdom tends to arrive only after all other alternatives have been exhausted. Happily, some of the most thoughtful innovators in AI and health seem to be getting there. Over the last several weeks I’ve had an unusual opportunity to speak before and engage with audiences of investment bankers, investors, operators, and even political scientists,... Read More
5
Nov
2026
RevMed’s Rollout, Yosemite Invests in Cancer & Servier’s Phase III Whiff
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2026
The AI Moment in Drug Discovery: Daphne Koller on The Long Run
Daphne Koller is today’s guest on The Long Run. Daphne is the founder and CEO of South San Francisco-based Insitro. It’s one of what you could call the first-generation companies that uses AI to speed up and improve drug discovery. Insitro was founded in 2018 and has secured $750 million in funding from venture capital firms and through partnerships with... Read More
31
Oct
2026
AI and Tocqueville at Harvard
I found myself this week back on my undergraduate campus, giving a seminar about “AI, Health, and Agency” for, of all things, Harvard’s Program in Constitutional Government, invited by Professor (emeritus) Harvey C. Mansfield, who at 94, remains sharper than most of us are or likely ever were. He is not only one of the university’s most distinguished scholars, but... Read More
30
Oct
2026
Anthropic Makes Noise, Silence Gets Bought, & GSK Gets HepB OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Oct
2026
Creating PROTACs and RIPTACs: Tim Shannon on The Long Run
Tim Shannon is today’s guest on The Long Run. Tim is a general partner at Canaan Partners. He was a pulmonary and critical care physician in the early part of his career, before moving over to R&D leadership in industry, and then eventually into venture capital investing. Tim got started as a VC during the Great Financial Crisis. That may... Read More
15
Oct
2026
BMS Hits IPF Goal, Iambic and City IPO & AZ Invests in Insitro
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Oct
2026
AAV Gene Therapy: What It Will Take To Get Through the Wilderness
When Luke first asked for my perspective on the state of AAV gene therapy over the summer, he asked me “Will AAV ever deliver on its early promise? Be safe? Be commercially successful?”. After ruminating for a while, I settled on the Stockdale paradox (as chronicled in Jim Collins’ Good to Great) as the best description of where we stand.... Read More
13
Oct
2026
Biotech IPO Scorecard: Triple the Action in 2026
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Oct
2026
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Oct
2026
Touch, Pain, and the Edge of Neuroscience: Ardem Patapoutian on The Long Run
Ardem Patapoutian is today’s guest on The Long Run. Ardem is a professor of neuroscience at Scripps Research in San Diego, and an investigator with Howard Hughes Medical Institute. His lab is focused on ion channels on the surface of cells that sense mechanical force, and how those signals are translated into our sense of touch, pain, and other basic... Read More
6
Oct
2026
Arboretum Gets $30M to Expand Molecular Dx for Healthcare & Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Sep
2026
Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Sep
2026
Long-Lasting Antibodies for Immune Diseases: Cameron Turtle on The Long Run
Cameron Turtle is today’s guest on The Long Run. Cameron is the CEO of Waltham, Mass.-based Spyre Therapeutics. The company is developing antibody drug candidates that are engineered to be longer-lasting than today’s drugs for immune disorders. This means patients could take fewer injections and the drugs should stay stable in the bloodstream to keep the disease under control longer.... Read More
17
Sep
2026
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Sep
2026
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2026
Drugs That Go Where None Could Before: Mathai Mammen on The Long Run
Mathai Mammen is today’s guest on The Long Run. Mathai is the CEO of Cambridge, Mass.-based Parabilis Medicines. The company has a platform for making drugs that hit elusive biological targets known as drivers of disease. Parabilis attacks them with alpha-helical peptide drug candidates that can get inside cells and bind with relatively flat and smooth surfaces of proteins. It... Read More
3
Sep
2026
Alumis & BioNTech Stumble, Lilly Buys Merida, & Takeda’s Latest FDA Approval
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Sep
2026
IYKYK: Leave the Vortex, Take the Influence
It’s not just your kids who aspire to become influencers. Attracting attention –- often through provocative content delivered through social media at high volume –- can seem increasingly like a business imperative, as the a16z co-founders have described (here, here) and, in the case of Andreessen, unhesitatingly embraced. The Attention Imperative But they’re not alone; many physicians, researchers, and policy... Read More
27
Aug
2026
RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.



